As AMD Drug Nears End of Phase I, Sirna Inks Ocular Disease Alliance with Allergan

The multi-year deal, which can be worth up to $250 million for Sirna, is in line with the RNAi company s plan to partner with bigger players on its drug-development programs. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.